Skip to content

PRTO: Held by 6 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Free TrialStart 14-Day Free Trial

Home›Companies›Protara Therapeutics, Inc. (PRTO)

Protara Therapeutics, Inc.

PRTO

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase2 readout (TARA-002): Dec 2025.

Share

Asset ManagementIPO: 2026Website ↗

The RCN Pareto Strategic Allocation ETF endeavors to achieve sustained growth in its investment value over an extended period.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

5.5/10

6 funds opened new positions●●

No recent insider activity●●

Phase3 readout expected Mar 2028●●

Held by 6 specialist funds●●

See how each signal contributes — fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

6 specialist funds hold PRTO with a Phase 3 in 534 days for Choline Chloride for Injection (Choline Deficiency, Liver Injury)

+2 more upcoming catalysts

RA Capital Management Driehaus Capital OrbiMed Advisors Perceptive Advisors Baker Bros. Advisors Boxer Capital

Fund Holdings

6 fund convergence

RA Capital Management

Driehaus Capital

OrbiMed AdvisorsNew

Perceptive Advisors

Baker Bros. AdvisorsHeld 7Q ↑

Position history (shares)

RA Capital Management

3Q Driehaus Capital

4Q Baker Bros. Advisors

AI Signal

PRTO: RA Capital Exit Signals Reassessment

RA Capital's exit from Protara marks a notable conviction reversal for a name held by six specialist funds including OrbiMed and Boxer Capital. The company's near-term catalyst (choline deficiency/liver injury Phase 3 readout March 2028) and lead program (TARA-002 in NMIBC Phase 3, April 2028) remain on track, but RA's departure suggests concerns around competitive positioning, commercial viability, or capital efficiency that the broader specialist consensus has yet to price in.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Feb 17, 2026

$11.9M

2 funds

May 15, 2026

$5.1M

1 fund

May 29, 2026

$0

0 funds

Aug 14, 2026

$12.2M

2 funds

+1041% total institutional value over 25 quarters

Catalysts

Phase 2Q4 2025TARA-002Lymphatic MalformationNCT05871970

Primary: Proportion of participants with clinical success after one treatment cycle of TARA-002 (8 weeks after the last injection)Enrollment:Target 38Sites: 11NA, TREATMENT

Phase 3Q1 2028Choline Chloride for InjectionCholine Deficiency, Liver InjuryNCT06910943

Phase 3Q2 2028TARA-002Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in SituNCT07480356

Phase 2Q4 2031TARA-002Non-muscle Invasive Bladder CancerNCT05951179

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ARA Capital Management4.9%Aug 14, 2025

SC 13G/ARA Capital Management9.9%Feb 14, 2025

SC 13GRA Capital Management10.0%Apr 25, 2024

SC 13G/AOrbiMed Advisors0.0%Feb 14, 2024

SC 13G/AOrbiMed Advisors6.0%Feb 14, 2023

SC 13G/ARock Springs Capital0.0%Feb 15, 2022

SC 13GOrbiMed Advisors6.0%Feb 11, 2022

SC 13G/ARock Springs Capital5.7%Feb 16, 2021

SC 13GRock Springs Capital6.2%Oct 2, 2020

Position Details

RA Capital ManagementEXITEDAug 14, 2026

Start free trial for share counts, dollar values & AI analysis

69 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

CRNX1 fund MIRM1 fund GLUE1 fund IMTX1 fund ABCL1 fund IDYA1 fund INSM1 fund NTLA1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: